Document Detail


Cyclosporin increases cellular idarubicin and idarubicinol concentrations in relapsed or refractory AML mainly due to reduced systemic clearance.
MedLine Citation:
PMID:  11243404     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The feasibility of adding both the multidrug resistance modulator cyclosporin (CsA) and granulocyte colony-stimulating factor (G-CSF) to a standard salvage regimen of idarubicin (IDA) and cytarabine was evaluated in patients with resistant or relapsed acute myeloid leukemia and myelodysplastic syndrome. Three patients received IDA 12 mg/m2/day, the next four patients 9 mg/m2/day. The dose of CsA was 16 mg/kg/day. Six patients showed Pgp expression and none MRP1 expression. Grade III or IV toxicity (CTC-NCIC criteria) was registered in six patients for gastrointestinal, two patients for cardiovascular and one patient for neurological complications. Three patients died in hypoplasia and three patients showed leukemic regrowth. Three control patients were treated with IDA 12 mg/m2/day and cytarabine, but no CsA and G-CSF. The plasma IDA and idarubicinol (ida-ol) area under the curve's of patients treated with IDA 12 mg/m2 plus CsA were higher (P< 0.05) than in controls. Cellular IDA concentrations were almost similar, but cellular ida-ol concentrations were significantly higher (P < 0.05) in the presence of CsA than in controls. We conclude that the toxicity either with IDA 12 or 9 mg/m2/day was too high. The modulating effect of CsA was mainly based on changes in plasma kinetics of IDA and ida-ol, although ida-ol cellular clearance was delayed in the presence of CsA.
Authors:
M Smeets; R Raymakers; P Muus; G Vierwinden; P Linssen; R Masereeuw; T de Witte
Related Documents :
23871344 - The association between hyperuricemia, left atrial size and new-onset atrial fibrillation.
15101714 - Myeloma of the central nervous system: strong association with unfavorable chromosomal ...
24511754 - Abcd2 score and bnp level in patients with tia and cerebral stroke.
3587624 - Chronic forms of borrelia burgdorferi infection of the nervous system.
14740704 - Long-term hemodynamic and electrocardiographic assessment following operative repair of...
11347834 - Hypofibrinolysis, thrombophilia, osteonecrosis.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Leukemia     Volume:  15     ISSN:  0887-6924     ISO Abbreviation:  Leukemia     Publication Date:  2001 Jan 
Date Detail:
Created Date:  2001-03-12     Completed Date:  2001-03-29     Revised Date:  2013-03-04    
Medline Journal Info:
Nlm Unique ID:  8704895     Medline TA:  Leukemia     Country:  England    
Other Details:
Languages:  eng     Pagination:  80-8     Citation Subset:  IM    
Affiliation:
Department of Hematology, University Medical Center Nijmegen, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Adolescent
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / pharmacology*,  therapeutic use
Cyclosporine / metabolism*,  pharmacology,  therapeutic use
Daunorubicin / analogs & derivatives,  metabolism,  pharmacokinetics*
Female
Humans
Idarubicin / metabolism,  pharmacokinetics*
Immunosuppressive Agents / pharmacology,  therapeutic use
Leukemia, Myeloid / drug therapy*,  metabolism,  pathology
Male
Middle Aged
Pilot Projects
Prospective Studies
Recurrence
Chemical
Reg. No./Substance:
0/Immunosuppressive Agents; 20830-81-3/Daunorubicin; 58957-92-9/Idarubicin; 59865-13-3/Cyclosporine; 86189-66-4/idarubicinol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following ...
Next Document:  Fusion of MOZ and p300 histone acetyltransferases in acute monocytic leukemia with a t(8;22)(p11;q13...